The novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a highly infectious viral disease that predominantly causes respiratory symptoms. Elevated liver enzymes have been reported during the course of disease and appear to be common. We present a 56‐year‐old woman with a history of decompensated alcoholic cirrhosis who presented with abdominal pain, fever and diarrhoea and was found to have acute on chronic liver failure secondary to SARS‐CoV‐2 infection. The patient was treated with empiric antibiotic and supportive care with subsequent improvement.
In order to determine the relationship between socioeconomic deprivation and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH), we retrospectively reviewed the electronic medical records of 1,430 patients in a large tertiary health care network in New York. These patients underwent liver biopsy over a 10-year period and were included in our study if they had evidence of NAFLD/NASH on liver biopsy. Zip codes were used to obtain data necessary to derive the social deprivation index (SDI) from the US Bureau of the Census. The high-SDI group was compared to the low-SDI group. Univariate and multivariate logistic regressions were performed to assess association between socioeconomic factors and NAFLD parameters, including presence of NASH (NAFLD activity score >4), moderate to severe steatosis (>33%), and significant fibrosis (S2-S4). We included 614 patients with NAFLD/ NASH; the median SDI was 31.5. Hemoglobin A1c values were higher in the high-SDI group compared to the low-SDI group (6.46 vs. 6.12, P = 0.02). Socioeconomic factors, such as private versus public health care, percentage being foreign born, percentage without a car, percentage with higher needs (<5 years old and >65 years old), and percentage currently living in renter-occupied and crowded housing units, showed statistically significant associations in predicting NASH. After adjusting for patient age, sex, race, body mass index, and diabetes, we saw a significant association between four or more socioeconomic parameters in predicting NASH (odds ratio [OR], 1.71; 95% confidence interval [CI], 1.099-2.856; P = 0.0190) and six or more socioeconomic parameters in predicting severe steatosis (OR, 1.498; 95% CI, 1.031-2.176; P = 0.0338) but no significant correlation between the number of socioeconomic parameters and significant fibrosis. Conclusion: Greater number of socioeconomic determinants (four or more) are associated with greater severity of NASH. Awareness of NAFLD/NASH needs to be raised in communities with high socioeconomic deprivation. (Hepatology Communications 2022;6:550-560).N onalcoholic fatty liver disease (NAFLD) has a current global prevalence of 24%, with nonalcoholic steatohepatitis (NASH) representing 25% of this population. NAFLD is expected to increase by approximately 30% globally, affecting 100 million people solely in the United States over the next decade. (1)(2)(3)(4) This increase in prevalence of NAFLD will predominately affect areas of growing urbanization and decreasing population size. (4) The increasing clinical impact of NAFLD is already becoming obvious. In the 5-year period between 2012 and 2017, there was greater than a 20% and 15% increase in deaths related to liver cancer and cirrhosis, respectively, in patients initially diagnosed with NAFLD/NASH. (5) In addition, it is well known that people with NAFLD are also at risk for cardiometabolic disease, nonhepatocellular carcinoma, malignancy, lung disease, and diabetes. (6,7) Globally, NAFLD stands as the number one cause of end-stage liver di...
Supplemental Digital Content is available in the text.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.